Study title:
Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32. Epub 2006 Jan 11.
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and
malignant peripheral nerve sheath tumours.
Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R,
Clausen M, Mautner VF.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: FLUDEOXYGLUCOSE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|